SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such the...

Descripción completa

Detalles Bibliográficos
Autores principales: Biederstädt, Alexander, Hassan, Zonera, Schneeweis, Christian, Schick, Markus, Schneider, Lara, Muckenhuber, Alexander, Hong, Yingfen, Siegers, Gerrit, Nilsson, Lisa, Wirth, Matthias, Dantes, Zahra, Steiger, Katja, Schunck, Kathrin, Langston, Steve, Lenhof, H-P, Coluccio, Andrea, Orben, Felix, Slawska, Jolanta, Scherger, Anna, Saur, Dieter, Müller, Stefan, Rad, Roland, Weichert, Wilko, Nilsson, Jonas, Reichert, Maximilian, Schneider, Günter, Keller, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Pancreas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398468/
https://www.ncbi.nlm.nih.gov/pubmed/32001555
http://dx.doi.org/10.1136/gutjnl-2018-317856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398468/
https://www.ncbi.nlm.nih.gov/pubmed/32001555
http://dx.doi.org/10.1136/gutjnl-2018-317856

Ejemplares similares